医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Ximedica Opens New Hong Kong Headquarters

2013年03月07日 AM01:10
このエントリーをはてなブックマークに追加


 

PROVIDENCE, R.I.

Ximedica, provider of comprehensive product development services to leading medical device makers and healthcare companies, announced that it has relocated its Hong Kong headquarters to the Hong Kong Science and Technology Park, a world-class hub for innovation and technology in the heart of the city’s biotech industry.

“Our new location gives us access not only to state of the art facilities needed to develop medical and diagnostic products of the future in the fast growing China market but similarly an opportunity to forge collaborations with a network of partners from around the world,” says Michael Pereira, Ximedica’s VP of Program Development and Engineering.

Relocating to the Hong Kong Science and Technology Park is a strategic move for Ximedica, largely because it allows access to advanced research, testing, and manufacturing facilities. The Park will host the company’s surgical, stem cell harvesting, wound management, drug delivery, and respiratory device research and development activities as well as office space for its employees.

Says Pereira, “the extensive laboratories and production facilities complement Ximedica’s integrated development process which begins with front-end technology assessment and ends with supply chain selection and management. Similar to our own integrated process, we see these extensive facilities as a means to save development costs and time.”

About Ximedica

Ximedica provides integrated human-centered research, product development, regulatory, and NPI manufacturing services to leading medical device and healthcare companies. Our goal is to help clients create and sustain profitable new business by providing commercially successful products. Ximedica is ISO 13485:2003 certified and FDA registered, with headquarters in Providence, Rhode Island and offices in Minnesota and Hong Kong. www.ximedica.com

CONTACT

Ximedica
Hope Hopkins, 401-330-3163 x149
Director of
Communications
hhopkins@ximedica.com

同じカテゴリーの記事 

  • ACC Moving to Cloud on the FINEOS Platform
  • Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
  • ザイード・サステナビリティ賞は5,900件を超える応募があり、世界的な広がりと影響力を実証しています
  • 扎耶德可持续发展奖展示全球影响力,收到超过5,900份申请
  • Poxel Provides an Update on Its Financial Position for the Second Quarter and First Half of 2024 and Announces the Rescheduling of Its Annual General Meeting